Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237512 | 0.97 | POLB (0.59) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| SCHEMBL9317140 | 0.93 | POLB (0.56) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5572604 | 0.93 | POLB (0.56) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| SCHEMBL1843440 | 0.88 | CXCR4 (0.77) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| SCHEMBL1841507 | 0.88 | CXCR4 (0.74) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| SCHEMBL12992865 | 0.88 | CXCR4 (0.62) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| SCHEMBL946201 | 0.88 | CXCR4 (0.62) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| SCHEMBL13334902 | 0.88 | POLB (0.52) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| SCHEMBL674657 | 0.87 | CXCR4 (0.83) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 | |
| SCHEMBL6657549 | 0.85 | CXCR4 (0.78) | CXCR4POLBSMN1; SMN2HSD17B10SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678725-A1 | CO-GRANULES COMPRISING BLEACHING CATALYST, BLEACHING ACTIVATOR, BINDER AND ZINC OR BISMUTH SALT, AND BLEACHING AND CLEANING AGENT COMPRISING SAME | Catexel GmbH (DE) | 2026-01-14 | — | — | EP | claimed |
| EP-4512880-A1 | LIQUID FORMULATION COMPRISING AN ALCOHOL AND HIGHLY WATER SOLUBLE MANGANESE COMPLEX SALT CATALYST, BLEACHING FORMULATION AND CLEANING AGENT COMPRISING THE SAME | WeylChem Performance Products GmbH (DE) | 2025-02-26 | — | — | EP | claimed |
| EP-4512881-A1 | LIQUID FORMULATION COMPRISING AN ALCOHOL AND HIGHLY WATER SOLUBLE MANGANESE COMPLEX SALT CATALYST, BLEACHING FORMULATION AND CLEANING AGENT COMPRISING THE SAME | Catexel GmbH (DE) | 2025-02-26 | — | — | EP | claimed |
| CN-119490893-A | Liquid formulations comprising alcohol and high water-soluble manganese complex salt catalysts, bleaching formulations and cleaners comprising the same | 卡特赛尔有限公司 | 2025-02-21 | — | — | CN | claimed |
| US-20250059474-A1 | Liquid formulation comprising an alcohol and highly water soluble manganese complex salt catalyst, bleaching formulation and cleaning agent comprising the same | CATEXEL GMBH (DE) | 2025-02-20 | — | — | US | claimed |
| CN-117285990-A | Composition comprising a protonated triazacyclic compound and manganese (II) acetate, preparation thereof, bleaching agent and cleaning agent | 韦尔化学性能产品有限公司 | 2023-12-26 | — | — | CN | claimed |
| EP-4214302-A1 | COMPOSITIONS COMPRISING BLEACHING CATALYST, MANUFACTURING PROCESS THEREOF, AND BLEACHING AND CLEANING AGENT COMPRISING SAME | WeylChem Performance Products GmbH (DE) | 2023-07-26 | — | — | EP | claimed |
| CN-116157497-A | Composition comprising a bleach catalyst, method for the production thereof and bleaching and cleaning agents comprising said composition | 韦尔化学性能产品有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-115590031-A | Disinfectant and using method thereof | 北京博诺安科科技有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| EP-4019554-A2 | METHOD OF PROCESSING SEAWEED AND RELATED PRODUCTS | Marine Biopolymers Ltd. (GB) | 2022-06-29 | — | — | EP | claimed |
| WO-2022058039-A1 | COMPOSITIONS COMPRISING BLEACHING CATALYST, MANUFACTURING PROCESS THEREOF, AND BLEACHING AND CLEANING AGENT COMPRISING SAME | WeylChem Performance Products GmbH (DE) | 2022-03-24 | — | — | WO | claimed |
| EP-3967742-A1 | COMPOSITIONS COMPRISING BLEACHING CATALYST, MANUFACTURING PROCESS THEREOF, AND BLEACHING AND CLEANING AGENT COMPRISING SAME | WeylChem Performance Products GmbH (DE) | 2022-03-16 | — | — | EP | claimed |
| EP-3176155-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | CATEXEL LTD (GB) | 2019-09-25 | — | — | EP | claimed |
| EP-3176155-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | Catexel Limited (GB) | 2017-06-07 | — | — | EP | claimed |
| EP-2590952-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE THEREOF | CATEXEL LTD (GB) | 2017-01-18 | — | — | EP | claimed |
| US-8907082-B2 | 1,2-bis-(4,7-dimethyl-1,4,7-triazacyclonon-1-yl)-ethane and intermediate for the synthesis of same | CATEXEL LIMITED (GB) | 2014-12-09 | — | — | US | claimed |
| US-20130261297-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | CATEXEL LIMITED (GB) | 2013-10-03 | — | — | US | claimed |
| US-12577371-B2 | Oxidatively curable coating composition | MILLIKEN INDUSTRIALS LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| WO-1997001360-A9 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | — | 1997-07-17 | — | — | WO | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577371-B2 | Oxidatively curable coating composition | TET1, JMJD6, SETDB1 | CXCR4 4324/4885POLB 591/4885SMN1; SMN2 1213/4885 |
| US-20130261297-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | DHPS, CYP51A1, BID | CXCR4 622/4885POLB 2364/4885SMN1; SMN2 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.